CME
Selection of BTK Inhibitor Following Frontline Chemoimmunotherapy in Older Patients With Comorbidities
Host: Mazyar Shadman, MD, MPH
Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all pat